- Home
- PWM vs PHGE Comparison
PWM vs PHGE Comparison
Compare PWM & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- PHGE
- Stock Information
- Founded
- PWM 2018
- PHGE 2015
- Country
- PWM Hong Kong
- PHGE Israel
- Employees
- PWM N/A
- PHGE N/A
- Industry
- PWM
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- PHGE Health Care
- Exchange
- PWM Nasdaq
- PHGE Nasdaq
- Market Cap
- PWM 12.4M
- PHGE 11.0M
- IPO Year
- PWM 2023
- PHGE N/A
- Fundamental
- Price
- PWM $0.36
- PHGE $0.46
- Analyst Decision
- PWM
- PHGE Strong Buy
- Analyst Count
- PWM 0
- PHGE 1
- Target Price
- PWM N/A
- PHGE $15.00
- AVG Volume (30 Days)
- PWM 179.5K
- PHGE 271.1K
- Earning Date
- PWM 07-07-2025
- PHGE 08-13-2025
- Dividend Yield
- PWM N/A
- PHGE N/A
- EPS Growth
- PWM N/A
- PHGE N/A
- EPS
- PWM N/A
- PHGE N/A
- Revenue
- PWM $639,912.00
- PHGE N/A
- Revenue This Year
- PWM N/A
- PHGE N/A
- Revenue Next Year
- PWM N/A
- PHGE N/A
- P/E Ratio
- PWM N/A
- PHGE N/A
- Revenue Growth
- PWM 83.60
- PHGE N/A
- 52 Week Low
- PWM $0.31
- PHGE $0.34
- 52 Week High
- PWM $2.70
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- PWM 43.36
- PHGE 44.42
- Support Level
- PWM $0.33
- PHGE $0.45
- Resistance Level
- PWM $0.37
- PHGE $0.51
- Average True Range (ATR)
- PWM 0.03
- PHGE 0.05
- MACD
- PWM -0.00
- PHGE 0.01
- Stochastic Oscillator
- PWM 33.00
- PHGE 55.56
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).